ProCE Banner Activity

Phase II Study of Novel BTK Inhibitor MK-1026 in Patients With R/R CLL/SLL

Slideset Download
Conference Coverage
MK-1026 was active and tolerable in this phase II study, which enrolled patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, including those who progressed on a previous BTK inhibitor.

Released: December 21, 2021

Expiration: December 20, 2022

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation